Mitotic inhibitors include-

Etoposide, Vincristine, Vinblastine, Teniposide, Vinorelbine tartarate 

Interacting drugs-summary

+ Vinorelbine -

Cisplatin

incidence of granulocytopenia with vinorelbine used in combination with cisplatin is significantly higher with than with single - agent vinorelbine

Mitomycin

acute pulmonary reactions have been reported with vinorelbine and other anticaner vinca alkaloids used in conjunction with mitomycin 

Non-small lung cancer

Mitotic inhibitors include-

Etoposide, Vincristine, Vinblastine, Teniposide, Vinorelbine tartarate 

Approved by FDA on December 23, 1994

Granulocytopenia. Mild to moderate peripheral neuropathy.

Alopecia. Mild to moderate nausea.

Chest pain, shortage of breath. Fatigue.

Patients with pretreatment granulocyte counts less than 1000cells/mm3

Special precautions:

Monitoring white blood counts. Bonr marrow .

Bronchospasm

acute shortage of breath. Eye contact.

Approved by FDA on December 23, 1994

Non-small lung cancer

Dosage:

The usual initial dose is 30mg/m2 administered weekly. The recommended method of administration is an IV injection over 6 to 10 minutes.

Mitotic inhibitors include-

Etoposide, Vincristine, Vinblastine, Teniposide, Vinorelbine tartarate 

1. Inform patients that the major acute toxicites of vinorelbine are related to bone marrow toxicity, specially granulocytopenia with increased susceptibility to infection.

2. Advise woman of child bearing potential to avoid pregnancy during treatment

Pharmacology:

Vinorelbine is a semi-synthetic vinca alkaloid with antitumor activity that interferes with microtubule assembly.

Pharmacokinetics:

Vinorelbine undergoes substantial hepatic elimination, with large amounts recovered in feces. The binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%. Vinorelbine binding was not altered in the presence of cisplatin.

Pregnancy:

Advise woman of child bearing potential to avoid becoming pregnant during therapy with vinorelbine.

Lactation:

Nursing should be discontinued in woman who are receiving vinorelbine therapy.